NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis

Company Overview

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Key Stats

• Today's Range: $16.00 to $16.58
• 50-Day Range: $14.90 to $24.07
• 52-Week Range: $14.06 to $27.29
• Volume: 122,394 shs
• Average Volume: 583,152 shs
• Market Capitalization: $1.77 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.33
• Consensus Rating: Buy

NewAmsterdam Pharma Stock Analysis - MarketRank™

NewAmsterdam Pharma scored higher than 43% of companies evaluated by MarketBeat, and ranked 603rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

NewAmsterdam Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

NewAmsterdam Pharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for NewAmsterdam Pharma are expected to decrease in the coming year, from ($1.75) to ($1.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NewAmsterdam Pharma is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NewAmsterdam Pharma is -6.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NewAmsterdam Pharma has a P/B Ratio of 4.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.37% of the float of NewAmsterdam Pharma has been sold short.

Short Interest Ratio / Days to Cover

NewAmsterdam Pharma has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in NewAmsterdam Pharma has recently increased by 23.04%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NewAmsterdam Pharma does not currently pay a dividend.

Dividend Growth

NewAmsterdam Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.37% of the float of NewAmsterdam Pharma has been sold short.

Short Interest Ratio / Days to Cover

NewAmsterdam Pharma has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in NewAmsterdam Pharma has recently increased by 23.04%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.66

News Sentiment

NewAmsterdam Pharma has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for NewAmsterdam Pharma this week, compared to 5 articles on an average week.

MarketBeat Follows

2 people have added NewAmsterdam Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, NewAmsterdam Pharma insiders have sold 2,685.04% more of their company's stock than they have bought. Specifically, they have bought $109,711.00 in company stock and sold $3,055,500.00 in company stock.

Percentage Held by Insiders

19.50% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NAMS Stock Analysis - Frequently Asked Questions

How have NAMS shares performed this year?

NewAmsterdam Pharma's stock was trading at $25.70 at the start of the year. Since then, NAMS shares have decreased by 37.2% and is now trading at $16.13.
View the best growth stocks for 2025 here.

How were NewAmsterdam Pharma's earnings last quarter?

NewAmsterdam Pharma (NASDAQ:NAMS) announced its earnings results on Wednesday, February, 26th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.47. The business had revenue of $12.77 million for the quarter, compared to analysts' expectations of $3.30 million.

Who are NewAmsterdam Pharma's major shareholders?

Top institutional shareholders of NewAmsterdam Pharma include Handelsbanken Fonder AB (0.24%) and Avanza Fonder AB (0.01%). Insiders that own company stock include Nap BV Forgrowth, James N Topper, Michael H Davidson, Louis G Lange, Louise Frederika Kooij, Juliette Berangere Audet and Johannes Jacob Piete Kastelein.
View institutional ownership trends.

How do I buy shares of NewAmsterdam Pharma?

Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NewAmsterdam Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NewAmsterdam Pharma investors own include Nextera Energy Partners (NEP), Enterprise Products Partners (EPD), Blue Owl Capital (OBDC), PIMCO Corporate & Income Opportunity Fund (PTY), PayPal (PYPL) and Ventyx Biosciences (VTYX).

Company Calendar

• Last Earnings: 2/26/2025
• Today: 4/17/2025
• Next Earnings (Estimated): 5/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NAMS
• CIK: 1936258
• Web: www.newamsterdampharma.com
• Phone: 352062971
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $43.33
• High Stock Price Target: $52.00
• Low Stock Price Target: $37.00
• Potential Upside/Downside: +170.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.61
• Quick Ratio: 10.61

Sales & Book Value

• Annual Sales: $45.56 million
• Price / Sales: 38.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.50 per share
• Price / Book: 4.58

Miscellaneous

• Outstanding Shares: 109,818,000
• Free Float: 74,371,000
• Market Cap: $1.76 billion
• Optionable: Optionable
• Beta: -0.01